Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Jun 1;63(11):1092-6.
doi: 10.1016/j.biopsych.2007.11.002. Epub 2007 Dec 21.

A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia

Tony P George  1 , Jennifer C Vessicchio, Kristi A Sacco, Andrea H Weinberger, Melissa M Dudas, Taryn M Allen, Cerissa L Creeden, Marc N Potenza, Alan Feingold, Peter I Jatlow
Affiliations
Randomized Controlled Trial

A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia

Tony P George et al. Biol Psychiatry. .

Abstract

Background: Individuals with schizophrenia smoke at higher rates (58%-88%) than the general population (approximately 22%), and have difficulty quitting. We determined whether the combination of sustained-release (SR) bupropion (BUP) with the transdermal nicotine patch (TNP) was well-tolerated and superior to placebo (PLO)+TNP for smoking cessation in schizophrenia.

Methods: A 10-week, double-blind, placebo-controlled trial of BUP (300 mg/day) in combination with TNP (21 mg/24h) for 58 outpatient smokers with schizophrenia was conducted. Primary outcome measures were continuous smoking abstinence in the last 4 weeks of the trial (Days 43-70) and 7-day point prevalence abstinence at 6 months post-target quit date (TQD) (week 26).

Results: Smokers assigned to the BUP+TNP group (n = 29) were more likely to achieve continuous smoking abstinence (8/29, 27.6%) than the PLO+TNP group (n = 29, 1/29, 3.4%) [Fisher's Exact Test, p < .05]; at 6-months post-TQD, 4/29 (13.8%) versus 0/29 (0.0%) achieved 7-day point prevalence smoking abstinence (p = .11). Neither bupropion SR nor smoking abstinence significantly altered the positive or negative symptoms of schizophrenia. The combination was well-tolerated in smokers with schizophrenia.

Conclusions: Combination therapy with bupropion SR+TNP versus placebo+TNP is well-tolerated and significantly improved short-term smoking abstinence in smokers with schizophrenia.

Trial registration: ClinicalTrials.gov NCT00124683.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Smoking Abstinence Rates in Bupropion SR and Placebo Groups during the 10-week Trial and at the Six Month Assessment. Abbreviations: BUP, Bupropion; PLO, placebo; TNP, transdermal nicotine patch; EOT, End of Trial; CA, Continuous Abstinence; 6MFU, Six Month Follow-up (Week 26) * Fisher’s Exact 2-Sided Test for EOT, p=0.056; CA, p<0.03; 6MFU, p=0.11
See this image and copyright information in PMC

References

    1. Kalman D, Morrisette SB, George TP. Co-morbidity of smoking with psychiatric and substance use disorders. Am J Addict. 2005;14:106–123. - PMC - PubMed
    1. Dalack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence and schizophrenia: clinical phenomenon and laboratory findings. Am J Psychiatry. 1998;155:1490–1501. - PubMed
    1. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Res. 2005;76:135–157. - PubMed
    1. Ziedonis DM, Williams JM. Management of smoking in people with psychiatric disorders. Curr Opin Psychiatry. 2003;16:305–315.
    1. Lasser K, Boyd JW, Woolhander S, Himmelstein DU, McCormick D, Bor DH. Smoking and mental illness: a population-based prevalence study. J Am Med Assoc. 2000;284:2606–2610. - PubMed

Publication types

MeSH terms

Associated data